IP Library Granted Patent US 11,821,891
Granted Patent B2
US 11,821,891 · App. 17/113,527 · Granted Nov 21, 2023

Erythrocyte aggregation and leukocyte isolation

Inventors: Jessica Godin Karp (Schenectady, NY); Xiaohui Chen (Schenectady, NY); Kashan Ali Shaikh (Clifton Park, NY); Mengli Wang (Rexford, NY); Ralf Lenigk (Schenectady, NY); Christine Lynne Surrette (Albany, NY)
Assignee: General Electric Company
G01N33/5002B01L3/502715B01L3/502738B01L3/502761B01L3/502769C12Q1/24G01N33/491B01D2313/18B01D2313/50B01L2200/0647B01L2300/16G01N2001/4088
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,821,891
App. No.
17/113,527
Granted
Nov 21, 2023
Kind
B2
Abstract

A device and/or methodology are described that include a mechanism for separating erythrocytes from other constituents of blood and for purifying leukocytes from blood. The separation and purification aspects may be provided in separate components or within the same component. The separation aspect assists in separating erythrocytes (red blood cells) from other cells in blood, such as by aggregation of the red blood cells. A suitable aggregation device or device component uses chambers with at least one small dimension (e.g., a microfluidic chip) to control the interaction of the blood with a solution containing a high molecular weight polymer (e.g., dextran) to achieve separation.

Claims (19)

1. A method, comprising:

loading a blood sample into a loading well on a first surface of a microfluidic device, wherein the loading well comprises a loading well outlet;

directing the blood sample from the loading well outlet into a vertical aggregation channel, via a vertical aggregation channel inlet coupled to the loading well outlet, wherein the vertical aggregation channel comprises a solution of high-molecular weight polysaccharide is present, wherein the blood sample has higher density than the solution, and wherein dimensions of the vertical aggregation channel enable stabilization of the higher density blood sample above the lower-density solution despite being energetically unstable, and wherein the vertical aggregation channel inlet is coupled to the loading well outlet at first longitudinal position along a longitudinal axis;

directing the blood sample along the longitudinal axis in a direction perpendicular to a horizontal interface formed between the solution and the blood sample;

aggregating red blood cells present in the blood sample at the horizontal interface formed between the solution and the blood sample, wherein the aggregated red blood cells sediment into the solution and out of the blood sample leaving a red blood cell separated sample; and

directing the aggregated red blood cells from a vertical aggregation channel outlet of the vertical aggregation channel to an output channel via an output channel inlet that is coupled to the vertical aggregation channel outlet at a second longitudinal position along the longitudinal axis, wherein the second longitudinal position is downstream of the first longitudinal position relative to the longitudinal axis.

2. The method of claim 1 , wherein the high-molecular weight polysaccharide comprises dextran.

3. The method of claim 1 , wherein the blood sample and solution are not mixed as part of the red blood cell aggregation step.

4. The method of claim 1 , wherein the vertical aggregation channel is sized so as to cause surface tension sufficient to maintain the higher-density blood layer over the lower-density solution.

5. The method of claim 1 , further comprising:

flowing at least a red blood cell depleted portion of the red blood cell separated sample over an affinity surface configured to bind one or more blood components.

6. The method of claim 5 , wherein the one or more blood components comprise one or more types of white blood cells.

7. The method of claim 5 , wherein the one or more blood components comprise one or more of plasma proteins, lipids, circulating nucleic acids, circulating tumor cells, viruses, or bacteria.

8. The method of claim 1 , wherein the blood sample is less than or equal to 100 μl whole blood.

9. The method of claim 1 , wherein an inner diameter the vertical aggregation channel tapers towards the second longitudinal position wherein each diameter of the output channel is substantially perpendicular to the longitudinal axis, wherein at least one diameter of the output channel is less than or equal to 450 μm.

10. The method of claim 1 , wherein the vertical aggregation channel in at least one dimension is less than or equal to 225 μm.

11. The method of claim 1 wherein the solution comprises a 1%-10% dextran concentration at a molecular weight of 100-1,500 kDa.

12. The method of claim 1 , comprising directing one or more reagents from one or more reagent wells to the loading well, wherein the one or more reagent wells are disposed adjacent to the loading well, and wherein the one or more reagent wells are fluidly coupled to a capture channel and configured to hold reagents for treating or analyzing cells captured by the capture channel.

13. The method of claim 1 , comprising directing the aggregated red blood cells from an output channel outlet of the output channel into a capture channel via a capture channel inlet that is coupled to the output channel outlet of the output channel at a third longitudinal position along the longitudinal axis, wherein the third longitudinal position is downstream of the second longitudinal position relative to the longitudinal axis, and the capture channel comprising an antibody coated surface configured to selectively bind at least one type of blood cell in the aggregated red blood cells, wherein the capture channel is downstream of the vertical aggregation channel.

Assignments (5)
QUITCLAIM ASSIGNMENT Recorded Sep 18, 2025
From: EDISON INNOVATIONS LLC
To: BLUE RIDGE INNOVATIONS, LLC
Reel/Frame 072938/0793 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2025
From: GENERAL ELECTRIC COMPANY
To: GE INTELLECTUAL PROPERTY LICENSING, LLC
Reel/Frame 070636/0815 →
CHANGE OF NAME Recorded Mar 26, 2025
From: GE INTELLECTUAL PROPERTY LICENSING, LLC
To: DOLBY INTELLECTUAL PROPERTY LICENSING, LLC
Reel/Frame 070643/0907 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2025
From: DOLBY INTELLECTUAL PROPERTY LICENSING, LLC
To: EDISON INNOVATIONS, LLC
Reel/Frame 070293/0273 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2020
From: KARP, JESSICA GODIN; CHEN, XIAOCHUI; SHAIKH, KASHAN ALI; WANG, MENGLI; LENIGK, RALF; SURRETTE, CHRISTINE LYNNE
To: GENERAL ELECTRIC COMPANY
Reel/Frame 054566/0783 →
Continuity (2)
Division 14956067 · Dec 1, 2015
Related Publication 20210088503A1 · Mar 25, 2021